- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04032821
To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects
April 7, 2021 updated by: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects,A Single Center, Open, Randomized, Single Dose, Two Period, Two Sequence, Crossover Phase I Clinical Trial
To evaluate the safety and tolerability of food to Alkotinib Capsules in healthy subjects
Study Overview
Detailed Description
Alkotinib is an insulin receptor tyrosine kinase inhibitor that selectively inhibits anaplastic lymphoma Kinase and proto-oncogene protein ROS1。Alkotinib is expected to be used in the treatment of ALK positive and ROS1 positive metastatic non-small cell lung Cancer and other cancers include patients with non-small cell lung cancer who are resistant to treatment with the first generation ALK inhibitor, such as kezotinib。
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130021
- The First Bethune Hospital of Jilin University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- sign the informed consent before the clinicaltrial, and fully understand the clinicaltrial content, process and possible adverse event.
- Be able to complete the research according to the clinicaltrial protocol.
- Subjects (including sexual partners) were willing to be screened up to 6 months after the last study drug administration No family planning and voluntary effective contraceptive measures, the specific contraceptive measures see appendix.
- Male and female subjects aged 18 to 55 years (including 18 and 55 years).
- The weight of male subjects should not be less than 50 kg and that of female subjects should not be less than 45 kg. The body of the Body mass index (BMI) = weight (kg)/height 2 (m2), with a BMI of 18~28 kg/m2 range (including critical value).
Normal or abnormal physical examination and vital signs have n
- clinical significance.
Exclusion Criteria:
- Smoking more than 5 cigarettes per day during the first 3 months of the study
- Allergic constitution (multiple drug and food allergies).
- A history of drug and/or alcohol abuse (14 units of alcohol per week: 1 unit = beer 285)ML, or liquor 25 mL, or wine 100 mL)
- Blood donation or massive blood loss within 3 months prior to clinical trial screening (> 450ml)
- Any drugs that alter liver enzyme activity were taken 28 days before screening.
- Within 14 days prior to screening,took any prescription, over-the-counter, vitamin products or Herbs.
- Special diet (including dragon fruit, mango, grapefruit, etc.) or drama in 2 weeks,before screening strenuous exercise or other factors affecting drug absorption, distribution, metabolism, excretion, etc.;
- CYP3A inhibitors (e.g., atanavir, talymycin, clarithromycin, etc.), CYP3A inducers (e.g Drugs metabolized by CYP2C8 (such as amodiaquine, silvastatin, etc.) and CYP2C9 metabolism Drugs such as diclofenac, ibuprofen, etc.
- There have been major changes in diet or exercise habits recently.
- Have taken a study drug or participated in a clinical trial of the drug within three months prior to taking the study drug Check.
- A history of dysphagia or any gastrointestinal illness that affects drug absorption, cholecystitis or cholecystectomy In addition to the history;
- Any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis or stomach and duodenum Ulcer etc.
- Subjects who could not tolerate standard meals
- Abnormal ecg has clinical significance, or QTc interval >450 ms, or heart rate or pulse < 55 times /Points.
- Any pulmonary disease, including but not limited to interstitial pneumonia, allergic pneumonia, occlusion.Bronchiolitis, pulmonary interstitial fibrosis,interstitial lung disease (ILD), or any pre-existing disease History.
- Female subjects were lactating during the screening period or during the test or had positive serum pregnancy results sex.
- Clinical laboratory examination has clinical significance abnormality, or other clinical findings within 12 months before screening the following diseases (including but not limited to gastrointestinal tract, heart, lung, kidney,Liver, pancreas, nerve, blood, endocrine, tumor, immune, mental or cardiovascular diseases).
- Screening for viral hepatitis (including hepatitis b and c), AIDS antibody and syphilis spirochete antibody positive.
- Ingested chocolate, any caffeine containing it or the yellow purinate-rich drug 48 hours before taking it.
- Any use of alcohol within 48 hours prior to taking the study drug.
- Positive urine screening or drug use in the past 5 years.
- Subjects considered to have other factors unsuitable for participation in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Alkotinib(300mg)First empty stomach, after the meal
Alkotinib(300mg),Subjects need to be fasting overnight for at least 10 hours before being warmed to 240 mL on an empty stomach Water service, lunch 4 hours later, dinner 10 hours later.
|
1. First empty stomach, after the meal.2.
After eating first, after fasting.
|
EXPERIMENTAL: Alkotinib(300mg)After eating first, after fasting
Alkotinib(300mg),Subjects need to be fasting for at least 10 hours overnight, starting 30 min before taking the medication A standard meal (800-1000 CAL) can be taken before taking the medicine, and 240 mL warm water can be taken after the meal Lunch hours later, dinner 10 hours later.
|
1. First empty stomach, after the meal.2.
After eating first, after fasting.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: up to 120 hours
|
Maximum blood concentration
|
up to 120 hours
|
AUC0-t
Time Frame: up to 120 hours
|
Area under the plasma concentration - time curve from 0 to the last measurable concentration time point t
|
up to 120 hours
|
AUC0-∞
Time Frame: up to 6 months
|
Area under the concentration - time curve from zero to infinity
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: up to 6 months
|
To the maximum blood concentration time
|
up to 6 months
|
t1/2
Time Frame: up to 6 months
|
Plasma drug half-life
|
up to 6 months
|
λz
Time Frame: up to 6 months
|
14/5000 The rate constant of plasma concentration elimination in terminal phase
|
up to 6 months
|
CL/F
Time Frame: up to 6 months
|
Apparent clearance
|
up to 6 months
|
VZ/F
Time Frame: up to 6 months
|
Apparent volume
|
up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: yanhua Ding, MD, The First Hospital of Jilin University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 20, 2019
Primary Completion (ACTUAL)
December 16, 2019
Study Completion (ACTUAL)
December 16, 2019
Study Registration Dates
First Submitted
July 23, 2019
First Submitted That Met QC Criteria
July 23, 2019
First Posted (ACTUAL)
July 25, 2019
Study Record Updates
Last Update Posted (ACTUAL)
April 12, 2021
Last Update Submitted That Met QC Criteria
April 7, 2021
Last Verified
July 1, 2020
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ZGALK003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No plan to share date of the trial
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on Alkotinib(300mg)
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompletedNon-small Cell Lung CancerChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingALK-positive Non-small Cell Lung CancerChina
-
Grupo Español de Tumores Huérfanos e InfrecuentesTakedaTerminatedMetastatic or Advanced Non-resectable Granulosa Cell Ovarian TumorsSpain
-
Chelsea and Westminster NHS Foundation TrustMerck Sharp & Dohme LLCRecruiting
-
Niguarda HospitalCompletedLeukemia, Myeloid, Chronic-PhaseItaly
-
Genzyme, a Sanofi CompanyCompletedUnresectable Locally Advanced or Metastatic, Medullary Thyroid CarcinomaJapan
-
AstraZenecaCompletedA Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy SubjectsHealthy Subjects | Pharmacokinetics | SafetyUnited States
-
Elif OralCompletedFatty Liver | Hypertriglyceridemia | NASH - Nonalcoholic Steatohepatitis | Familial Partial LipodystrophyUnited States
-
Johns Hopkins UniversityCompletedHepatitis C | End Stage Renal DiseaseUnited States
-
Kirby InstituteCompletedHepatitis C, ChronicUnited States, United Kingdom, Australia, France, New Zealand, Canada, Switzerland, Germany